RxDoctor Payments Data

Uchechi Opaigbeogu, MD

Family Medicine · Oxon Hill, MDNPI 1033215371

Payments from drug & device makers

$2,194in general payments, 2019–2025

Across 95 payments — averaging $23.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$567
  • Novartis$313
  • AstraZeneca$312
  • Sunovion Pharmaceuticals Inc.$234
  • Novo Nordisk$215
  • Scilex Pharmaceuticals Inc.$179
  • plus $374 from 14 others

What the payments were for

  • Food & beverage$2,194100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,194 in reported general payments places this provider in the 75th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$418,880
Medicare patients
274
Services billed
3,916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban384$117,776
JardianceEmpagliflozin234$72,699
JanuviaSitagliptin Phosphate239$67,538
BiktarvyBictegrav/Emtricit/Tenofov Ala13$54,786
LokelmaSodium Zirconium Cyclosilicate58$24,578
XareltoRivaroxaban63$21,312
OzempicSemaglutide12$19,674
EntrestoSacubitril/Valsartan38$16,579
TrulicityDulaglutide18$16,310
LinzessLinaclotide11$13,339
Etravirine11$13,322
Atorvastatin Calcium721$10,773
VeltassaPatiromer Calcium Sorbitex27$9,742
Darunavir12$9,643
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog64$8,241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$14$79,459247 claims
GileadBiktarvy$23$54,78613 claims
AstraZenecaLokelma, Farxiga$312$31,55282 claims
Novo NordiskOzempic$215$19,67412 claims
NovartisEntresto$313$16,57938 claims
AbbVieLinzess$12$13,33911 claims
BayerKerendia$567$3,94212 claims
GSKArnuity Ellipta$23$3,68614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Oxon Hill

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →